Eyal C. Attar Sells 10,334 Shares of Vor Biopharma Inc. (NYSE:VOR) Stock

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) insider Eyal C. Attar sold 10,334 shares of the firm's stock in a transaction dated Friday, December 27th. The stock was sold at an average price of $1.25, for a total value of $12,917.50. Following the completion of the sale, the insider now directly owns 81,439 shares in the company, valued at approximately $101,798.75. The trade was a 11.26 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Vor Biopharma Price Performance

NYSE VOR traded down $0.08 during trading hours on Tuesday, hitting $1.11. The company had a trading volume of 813,965 shares, compared to its average volume of 538,580. The firm's 50 day moving average is $0.88 and its 200 day moving average is $0.89. The company has a market capitalization of $76.23 million, a price-to-earnings ratio of -0.67 and a beta of -0.37. Vor Biopharma Inc. has a fifty-two week low of $0.63 and a fifty-two week high of $3.14.

Vor Biopharma (NYSE:VOR - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.40). On average, equities analysts anticipate that Vor Biopharma Inc. will post -1.55 EPS for the current year.

Institutional Trading of Vor Biopharma

Hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC boosted its stake in shares of Vor Biopharma by 51.4% in the second quarter. Acadian Asset Management LLC now owns 81,305 shares of the company's stock valued at $79,000 after purchasing an additional 27,597 shares during the period. Hsbc Holdings PLC boosted its position in Vor Biopharma by 177.0% in the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company's stock valued at $51,000 after buying an additional 31,333 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Vor Biopharma during the second quarter valued at about $53,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Vor Biopharma during the second quarter worth about $63,000. Finally, Exchange Traded Concepts LLC increased its position in shares of Vor Biopharma by 40.8% during the third quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company's stock worth $116,000 after acquiring an additional 48,017 shares during the last quarter. Hedge funds and other institutional investors own 97.29% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on VOR shares. JMP Securities reaffirmed a "market outperform" rating and set a $12.00 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. Robert W. Baird dropped their price objective on Vor Biopharma from $22.00 to $14.00 and set an "outperform" rating for the company in a report on Friday, November 8th. Wedbush reiterated an "outperform" rating and issued a $11.00 target price on shares of Vor Biopharma in a report on Monday, December 9th. Finally, HC Wainwright restated a "buy" rating and set a $17.50 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $11.36.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.